Stock·NASDAQ·Healthcare
Recursion Pharmaceuticals, Inc. (RXRX)
- Market cap
- $2.23B
- Dividend yield
- 0.00%
- Street target
- $7.00median of 7 analysts
- 52-week range
- $2.77 $7.18
The short version
Where RXRX stands today, in four lines, and what CleaRank Financial AI makes of it.
RXRX at a glance
Recursion Pharmaceuticals, Inc. (RXRX): Hold, 50/100 on CleaRank's AI score.
- Trend Up: the price is above both its 50- and 200-day moving averages ($3.62 and $3.57).
- Earnings RXRX beat estimates in 2 of its last 6 quarters, yet fell the next day after every one of them.
- Insiders Insiders sold $13.6M and made no open-market purchases over the last 18 months.
Figures as of October 16, 2026.
CleaRank Financial AI
Recursion Pharmaceuticals (RXRX) is currently trading at $4.16, above its 50-day SMA of $3.62 and 200-day SMA of $3.57, indicating some recent positive price momentum.
The company's financial performance shows a substantial revenue decline of -60.1% year-over-year, coupled with a negative EPS of -1.00 and a significantly negative profit margin of -945.90%. Despite these fundamental challenges, Wall Street analysts maintain a 'Buy' consensus with a median price target of $7.00, suggesting an upside potential of 68.3% from the current price. However, insider activity reveals significant net selling, with over $13.6 million in sales versus no reported purchases, signaling a lack of insider confidence.
Only on CleaRank
Figures we compute ourselves from RXRX's own price, earnings and insider-filing history. Tap one to see it in context.
Price and trading
The chart, today's range and how far the price has moved over each period.
Trend checks
3/4Price above its 50-day average ›
The price of $4.16 is 14.9% above the 50-day simple moving average of $3.62.Price above its 200-day average ›
The price is 16.7% above the 200-day simple moving average of $3.57.50-day average above the 200-day ›
The 50-day average ($3.62) is 1.5% above the 200-day average ($3.57), the arrangement of a rising longer-term trend.In the upper half of its 52-week range ›
The price sits at 32% of its 52-week range, between $2.77 and $7.18.
RXRX share price
Pick a period: each tab shows how far RXRX has moved over it, to the last close.
Today's trading
Where RXRX sits inside today's range and its 52-week range.
Fundamentals
Valuation against the sector, and the revenue and earnings behind it.
Valuation and quality checks
0/3P/S below the sector median ›
The price-to-sales ratio of 36.56 is 975.4% above the sector median of 3.4.Profitable over the last 12 months ›
Net income over the last 12 months was $-518.9M on revenue of $54.9M, a net margin of -945.9%.Beat estimates in most recent reports ›
RXRX beat the EPS estimate in 2 of its last 6 reports.
Key statistics
The headline figures for RXRX.
As of October 16, 2026, RXRX trades at $4.16, with a market value of $2.23B and no P/E ratio (its trailing earnings are negative).
What the numbers say
CleaRank Financial AI's reading of RXRX's valuation, growth and risks.
Recursion Pharmaceuticals exhibits a high price-to-sales ratio of 36.56, significantly above the sector median of 3.4, suggesting the stock is richly valued relative to its current revenue.
The company's profitability remains a concern, with a negative profit margin of -945.90% and a negative return on equity of -56.58%, far below the sector averages. While the debt-to-equity ratio is low at 0.07, indicating minimal leverage, the substantial revenue contraction of -60.1% raises questions about the company's growth trajectory and ability to achieve profitability. The current valuation appears disconnected from its fundamental performance.
RXRX against the Healthcare sector
How RXRX compares with the median Healthcare stock CleaRank tracks.
Price to sales vs sector: On price-to-sales, the yardstick used here in place of P/E, RXRX trades at 36.56x, far above the sector average of 3.40x.
Return vs XLV: Since May 5, 2025, RXRX has lost 12.5% against a gain of 28.9% for XLV.
Performance against XLV
RXRX and the Healthcare sector fund over the same days.
Revenue and earnings
How much RXRX sells, and how much of it becomes profit.
Revenue growth: Revenue grew 27.0% in FY2025 to $74.3M, from $58.5M a year earlier.
Profit margin: The net margin was -868.3% in FY2025, down from -792.7% the year before.
Loss-making: RXRX lost $645M in FY2025.
Earnings reality check
Did RXRX beat what analysts expected, and how did the stock react?
Earnings record: RXRX beat the analyst estimate in 2 of the last 6 quarters.
Market reaction: The stock fell in the first session after 2 of those 2 beats, so a beat has not been enough on its own.
| Report | Estimate | Actual | Surprise | First session | 5 sessions |
|---|---|---|---|---|---|
| Aug 5, 2026after close | -$0.23 | -$0.25 | -8.70% | +0.32% | +3.79% |
| Nov 5, 2025after close | -$0.38 | -$0.36 | +5.26% | -6.85% | -6.25% |
| Aug 5, 2025after close | -$0.35 | -$0.41 | -17.14% | -0.90% | -2.17% |
| May 5, 2025after close | -$0.52 | -$0.50 | +3.85% | -12.62% | -2.42% |
| Feb 28, 2025after close | -$0.42 | -$0.53 | -26.19% | -12.25% | -12.25% |
| Nov 6, 2024after close | -$0.33 | -$0.34 | -3.03% | -0.57% | +5.02% |
As of October 16, 2026, RXRX has beaten the analyst EPS estimate in 2 of its last 6 reported quarters and fell in the first trading session after 2 of those beats; its latest report, on August 5, 2026, came in 8.70% below the estimate and the stock moved +0.32% in the first session.
The first session is the first full trading day on the news: the report day itself for a report before the open, the next day for one after the close. Surprise is actual EPS against the consensus estimate.
AI analysis and technicals
CleaRank's score and reasoning, the indicators behind it, and what the price moves with.
Momentum checks
3/3RSI not overbought or oversold ›
The 14-day RSI is 54.3, in neutral territory.RSI above 50 ›
An RSI of 54.3 is above the 50 midpoint, so buyers have had the upper hand over the last 14 days.MACD line above zero ›
The MACD line is positive, so the 12-day average is above the 26-day average.
CleaRank AI analysis of RXRX
The score, the reasoning behind it, and what could move the price next.
Recursion Pharmaceuticals' stock is currently trading above its 50-day simple moving average (SMA) at $3.62 and its 200-day SMA at $3.57, suggesting a short-to-medium term uptrend.
The 14-day Relative Strength Index (RSI) is at 54.33, indicating neutral momentum. The Moving Average Convergence Divergence (MACD) is at 0.13, also suggesting a lack of strong directional conviction. Volume has been significantly above average, with the latest volume at 62.8 million compared to an average of 38.9 million, indicating increased investor interest around the current price levels.
Analyst Price Targets Suggest Upside ›
The median analyst price target of $7.00 suggests a potential upside of 68.3% from the current stock price, indicating some analyst optimism.
Source: Wall Street SummaryTrading Above Key Moving Averages ›
The stock is currently trading above its 50-day and 200-day moving averages ($3.62 and $3.57), indicating positive short-to-medium term price momentum.
Source: Technical Analysis
Significant Insider Selling ›
Insiders have sold over $13.6 million in stock with no reported purchases.
Source: Insider Trading DataContinued Revenue Contraction ›
Revenue is projected to decline by -60.1% year-over-year, with further contractions expected in the upcoming quarters, posing a significant challenge to growth.
Source: Wall Street Estimates
- The stock is trading above its 50-day and 200-day moving averages ($3.62 and $3.57), but the neutral RSI suggests caution before entering new positions.
Technical indicators
Momentum and trend for RXRX, from its daily closes.
As of October 16, 2026, with RXRX at $4.16, its 14-day RSI is 54.3 (neutral territory), its 50-day simple moving average is $3.62 and its 200-day is $3.57.
Calculated by CleaRank on daily closes as of October 16, 2026: Wilder's 14-day RSI, 50- and 200-day simple moving averages, MACD line (12, 26).
What RXRX moves with
Correlation of daily returns over one year: +1 moves in step, 0 has no link, -1 moves the opposite way.
As of October 16, 2026, RXRX's 1-year correlation of daily returns is +0.53 with S&P 500 (SPY), +0.53 with Nasdaq 100 (QQQ), +0.43 with Bitcoin (BTC) and +0.20 with gold (XAU).
What Wall Street expects
The analysts' target range and how their ratings split.
Analysts checks
2/3Most analysts rate it a buy ›
3 of 7 analysts rate it a buy or strong buy, 4 a hold and 0 a sell.Median target above the price ›
The median 12-month target of $7.00 is 68.3% above the price.More buy ratings than three months ago ›
3 of 7 rate it a buy now, against 3 of 8 three months ago.
RXRX Wall Street View
12-month price targets
Ratings
Recent rating actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 14, 2026 | Morgan Stanley | Maintains | Equal-Weight |
| May 7, 2026 | Needham | Reiterates | Buy |
| Apr 30, 2026 | JP Morgan | Maintains | Overweight |
As of October 16, 2026, 7 Wall Street analysts cover RXRX: 3 rate it a buy or strong buy, 4 a hold and 0 a sell or strong sell. Their 12-month price targets range from $4.00 to $10.00, with a median of $7.00, 68.3% above the price of $4.16.
Source: TwelveData analyst consensus. Targets and ratings belong to the analysts, not to CleaRank.
A trade plan, if you want one
Entry, stop and target levels from the moving averages and recent volatility. Educational, not advice.
RXRX trade plan
Entry, stop and target levels, sized to your account. Change the bias or the risk and every level updates.
Entry Strategies pick an entry style
Risk management
Profit targets (Based on Conservative Entry)
RXRX moves about 6.6% a day on average, so a stop can fill well past its level. Educational levels, not financial advice; the full disclaimer is at the foot of the page.
Risk profile
How much RXRX tends to move, against the market and on its own.
The long record
RXRX's worst falls and recoveries, what $10,000 became, and which months have been kind to it.
Track record checks
0/4Average daily move under 2% ›
The price has moved 6.62% on an average day (30-day standard deviation of daily returns).Recovered from its worst fall ›
The worst fall was 93.1%, from July 2021 to March 2026; the price is still 89.9% below that peak.Most 1-year holds ended higher ›
20% of 1-year holding periods in the last 6 years ended with a gain.Beat the S&P 500 since the chart begins ›
$10,000 invested in April 2021 is now worth $1,329.07, against $19,900 in the S&P 500 (SPY).
RXRX Drawdowns & Recovery
As of October 16, 2026, RXRX's worst peak-to-trough fall over the last 6 years with dividends reinvested was -93.1% (July 2021 to March 2026); it is still 89.9% below that peak, and 20% of 1-year holding periods ended with a gain.
From weekly closing values with dividends reinvested. A drawdown is the fall from the highest value reached so far to a later low.
Growth of $10,000
What $10,000 put into RXRX in April 2021 is worth now, against the same amount in the S&P 500.
Against the market: RXRX trailed the S&P 500 over this period: $1,329.07 against $19,900.
A $10,000 investment in RXRX in April 2021 would be worth about $1,329 today with dividends reinvested, compared with about $19,900 for the same investment in the S&P 500 benchmark (also with dividends reinvested).
Seasonal patterns
Which calendar months have been kind to RXRX, and which have not.
Strongest month, June: an average of +15.98%, up in 4 of 6 years.
Weakest month, March: an average of -24.92%, up in 0 of 5 years.
This month, October: has averaged -5.56%, up in 1 of 5 years. Past seasonality does not repeat on schedule.
Over the last 6 years, RXRX's strongest calendar month has been June (average +15.98%, up in 4 of 6 years) and its weakest March (average -24.92%, up in 0 of 5 years).
Average return for each calendar month over the last 6 years, from weekly closing prices with dividends included.
Long-term scenarios
Thousands of simulated paths from the price history. A range of outcomes, not a forecast.
Monte Carlo projection
Thousands of simulated paths for $10,000 in RXRX, from its own past volatility. The shaded area holds 80% of them.
CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in RXRX today could grow to about $3,389 by 2036 in the base case, with a 90th-percentile outcome near $25,715 and a 10th-percentile outcome around $447. Projections are statistical simulations, not guarantees.
RXRX Stock Price Prediction: 2030
The same simulation in share prices, year by year.
CleaRank's simulation projects a price near $2.70 for RXRX by 2030 in the base case, from $4.16 today (0.6x over 4 years). The 10th-percentile path ends near $0.7491. These are outcomes of a Monte Carlo simulation run on RXRX's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | 10th percentile | Base case | 90th percentile | range base today |
|---|---|---|---|---|
| 2027 | $1.97 | $3.73 | $7.09 | |
| 2028 | $1.35 | $3.35 | $8.29 | |
| 2029 | $0.9911 | $3.01 | $9.12 | |
| 2030 | $0.7491 | $2.70 | $9.72 | |
| 2031 | $0.5779 | $2.42 | $10.15 |
Method: a lognormal simulation of RXRX's own volatility and capped historical trend, re-run daily; base case is the median path, the outer columns the 10th and 90th percentiles.
Insider trading
What the people running the company have bought and sold.
RXRX insider trading
Shares the company's directors and officers bought and sold, from their own filings.
Month by month
Open-market purchases above the line, sales below.
Insider buying: No insider bought RXRX shares on the open market in the last 18 months. Sales are often planned in advance or cover tax on vesting shares, so they say less than purchases would.
As of October 16, 2026, RXRX insiders reported 41 open-market sales worth $13.6M and no open-market purchases over the last 18 months; grants and option exercises are not counted.
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Oct 6, 2026 | Blake Charles Borgeson
Director
|
Sell | 50.0K | $242.0K |
| Oct 6, 2026 | Robert M Hershberg
Director
|
Sell | 25.0K | $125.0K |
| Oct 6, 2026 | Robert M Hershberg
Director
|
Option | 25.0K | $55.5K |
| Sep 8, 2026 | Najat Khan
Chief Executive Officer
|
Sell | 22.4K | $78.8K |
| Sep 1, 2026 | Blake Charles Borgeson
Director
|
Sell | 30.0K | $100.2K |
| Aug 4, 2026 | Blake Charles Borgeson
Director
|
Sell | 30.0K | $97.5K |
| Jul 7, 2026 | Blake Charles Borgeson
Director
|
Sell | 40.0K | $158.5K |
| Jul 1, 2026 | Zavain Dar
Director
|
Grant | 5.1K | - |
| Jul 1, 2026 | Dean Y Li
Director
|
Grant | 3.7K | - |
| Jun 18, 2026 | Namandje N. Bumpus
Director
|
Sell | 4.0K | $12.6K |
| Jun 17, 2026 | Blake Charles Borgeson
Director
|
Grant | 88.4K | - |
| Jun 17, 2026 | Namandje N. Bumpus
Director
|
Grant | 88.4K | - |
| Jun 17, 2026 | Zavain Dar
Director
|
Grant | 88.4K | - |
| Jun 17, 2026 | Robert M Hershberg
Director
|
Grant | 88.4K | - |
| Jun 17, 2026 | Dean Y Li
Director
|
Grant | 88.4K | - |
| Jun 17, 2026 | Franziska Ph.d. Michor
Director
|
Grant | 88.4K | - |
| Jun 17, 2026 | Elaine D Sun
Director
|
Grant | 88.4K | - |
| Jun 5, 2026 | Christopher C. Gibson
Director
|
Sell | 40.0K | $144.8K |
| Jun 5, 2026 | Najat Khan
Chief Executive Officer
|
Sell | 23.6K | $84.5K |
| Jun 5, 2026 | Christopher C. Gibson
Director
|
Grant | 40.0K | - |
| Jun 3, 2026 | Namandje N. Bumpus
Director
|
Sell | 4.4K | $15.5K |
| Jun 2, 2026 | Blake Charles Borgeson
Director
|
Sell | 30.0K | $110.4K |
| May 22, 2026 | Christopher C. Gibson
Director
|
Sell | 40.0K | $123.2K |
| May 22, 2026 | Christopher C. Gibson
Director
|
Grant | 40.0K | - |
| May 7, 2026 | Christopher C. Gibson
Director
|
Sell | 40.0K | $134.8K |
| May 7, 2026 | Christopher C. Gibson
Director
|
Grant | 20.0K | - |
| May 7, 2026 | Christopher C. Gibson
Director
|
Grant | 60.0K | - |
| May 5, 2026 | Blake Charles Borgeson
Director
|
Sell | 30.0K | $105.6K |
| Apr 7, 2026 | Christopher Gibson
Director
|
Sell | 40.0K | $124.0K |
| Apr 7, 2026 | Blake Charles Borgeson
Director
|
Sell | 30.0K | $93.0K |
| Apr 7, 2026 | Christopher Gibson
Director
|
Grant | 40.0K | - |
| Apr 1, 2026 | Zavain Dar
Director
|
Grant | 4.9K | - |
| Apr 1, 2026 | Dean Y Li
Director
|
Grant | 3.3K | - |
| Mar 23, 2026 | Christopher Gibson
Director
|
Sell | 40.0K | $130.0K |
| Mar 23, 2026 | Christopher Gibson
Director
|
Grant | 40.0K | - |
| Mar 17, 2026 | Ben R Taylor
Chief Financial Officer
|
Sell | 8.0K | $27.0K |
| Mar 9, 2026 | Najat Khan
Chief Executive Officer
|
Sell | 28.3K | $94.7K |
| Mar 9, 2026 | Christopher Gibson
Director
|
Grant | 20.0K | - |
| Mar 9, 2026 | Christopher Gibson
Director
|
Grant | 20.0K | - |
| Mar 3, 2026 | Blake Charles Borgeson
Director
|
Sell | 170.0K | $588.2K |
| Feb 19, 2026 | Christopher Gibson
Director
|
Sell | 40.0K | $138.4K |
| Feb 19, 2026 | Christopher Gibson
Director
|
Grant | 40.0K | - |
| Feb 18, 2026 | Ben R Taylor
Chief Financial Officer
|
Sell | 13.4K | $41.4K |
| Feb 6, 2026 | Hallett David
Officer
|
Grant | 526.3K | - |
| Feb 6, 2026 | Christopher Gibson
Director
|
Grant | 30.3K | - |
| Feb 6, 2026 | Najat Khan
Chief Executive Officer
|
Grant | 1.7M | - |
| Feb 6, 2026 | Ben R Taylor
Chief Financial Officer
|
Grant | 470.5K | - |
| Feb 4, 2026 | Christopher Gibson
Director
|
Sell | 40.0K | $164.8K |
| Feb 4, 2026 | Christopher Gibson
Director
|
Grant | 40.0K | - |
| Feb 3, 2026 | Blake Charles Borgeson
Director
|
Sell | 220.0K | $924.0K |
| Jan 20, 2026 | Christopher Gibson
Director
|
Sell | 40.0K | $178.8K |
| Jan 20, 2026 | Christopher Gibson
Director
|
Grant | 40.0K | - |
| Jan 6, 2026 | Blake Charles Borgeson
Director
|
Sell | 220.0K | $959.2K |
| Jan 5, 2026 | Christopher Gibson
Director
|
Sell | 40.0K | $170.0K |
| Jan 5, 2026 | Christopher Gibson
Director
|
Grant | 60.0K | - |
| Jan 5, 2026 | Christopher Gibson
Director
|
Grant | 20.0K | - |
| Jan 2, 2026 | Zavain Dar
Director
|
Grant | 3.6K | - |
| Jan 2, 2026 | Dean Y Li
Director
|
Grant | 2.4K | - |
| Dec 29, 2025 | Ben R Taylor
Chief Financial Officer
|
Sell | 21.4K | $89.4K |
| Dec 22, 2025 | Najat Khan
Officer and Director
|
Sell | 124.4K | $548.6K |
| Dec 19, 2025 | Christopher Gibson
Chief Executive Officer
|
Sell | 40.0K | $180.0K |
| Dec 19, 2025 | Christopher Gibson
Chief Executive Officer
|
Grant | 40.0K | - |
| Dec 4, 2025 | Christopher Gibson
Chief Executive Officer
|
Sell | 40.0K | $185.2K |
| Dec 4, 2025 | Christopher Gibson
Chief Executive Officer
|
Grant | 20.0K | - |
| Dec 4, 2025 | Christopher Gibson
Chief Executive Officer
|
Grant | 60.0K | - |
| Dec 2, 2025 | Blake Charles Borgeson
Director
|
Sell | 220.0K | $961.4K |
| Nov 19, 2025 | Christopher Gibson
Chief Executive Officer
|
Sell | 40.0K | $166.4K |
| Nov 19, 2025 | Christopher Gibson
Chief Executive Officer
|
Grant | 40.0K | - |
| Nov 5, 2025 | Najat Khan
Officer and Director
|
Grant | 84.9K | - |
| Nov 4, 2025 | Christopher Gibson
Chief Executive Officer
|
Sell | 40.0K | $208.4K |
| Nov 4, 2025 | Christopher Gibson
Chief Executive Officer
|
Grant | 60.0K | - |
| Nov 4, 2025 | Christopher Gibson
Chief Executive Officer
|
Grant | 20.0K | - |
| Oct 23, 2025 | Christopher Gibson
Chief Executive Officer
|
Sell | 100.0K | $570.0K |
| Oct 23, 2025 | Christopher Gibson
Chief Executive Officer
|
Grant | 100.0K | - |
| Oct 10, 2025 | Christopher Gibson
Chief Executive Officer
|
Sell | 100.0K | $604.0K |
| Oct 10, 2025 | Christopher Gibson
Chief Executive Officer
|
Grant | 20.0K | - |
| Oct 10, 2025 | Christopher Gibson
Chief Executive Officer
|
Grant | 120.0K | - |
| Oct 1, 2025 | Zavain Dar
Director
|
Grant | 2.9K | - |
| Oct 1, 2025 | Dean Y Li
Director
|
Grant | 2.0K | - |
| Sep 25, 2025 | Christopher Gibson
Chief Executive Officer
|
Sell | 100.0K | $476.0K |
| Sep 25, 2025 | Christopher Gibson
Chief Executive Officer
|
Grant | 100.0K | - |
| Sep 10, 2025 | Christopher Gibson
Chief Executive Officer
|
Sell | 100.0K | $471.0K |
| Sep 10, 2025 | Christopher Gibson
Chief Executive Officer
|
Grant | 20.0K | - |
| Sep 10, 2025 | Christopher Gibson
Chief Executive Officer
|
Grant | 120.0K | - |
| Aug 26, 2025 | Christopher Gibson
Chief Executive Officer
|
Sell | 100.0K | $484.0K |
| Aug 26, 2025 | Christopher Gibson
Chief Executive Officer
|
Grant | 100.0K | - |
| Aug 18, 2025 | Najat Khan
Officer and Director
|
Sell | 36.6K | $202.2K |
| Aug 11, 2025 | Christopher Gibson
Chief Executive Officer
|
Sell | 618.2K | $3.3M |
| Aug 11, 2025 | Christopher Gibson
Chief Executive Officer
|
Grant | 10.0K | - |
| Aug 11, 2025 | Christopher Gibson
Chief Executive Officer
|
Grant | 541.5K | - |
| Jul 1, 2025 | Zavain Dar
Director
|
Grant | 2.9K | - |
| Jul 1, 2025 | Dean Y Li
Director
|
Grant | 1.9K | - |
| Jun 18, 2025 | Blake Charles Borgeson
Director
|
Grant | 22.0K | - |
| Jun 18, 2025 | Namandje N. Bumpus
Director
|
Grant | 11.0K | - |
| Jun 18, 2025 | Zavain Dar
Director
|
Grant | 22.0K | - |
| Jun 18, 2025 | Robert M Hershberg
Director
|
Grant | 22.0K | - |
| Jun 18, 2025 | Dean Y Li
Director
|
Grant | 22.0K | - |
| Jun 18, 2025 | Franziska Ph.d. Michor
Director
|
Grant | 22.0K | - |
| Jun 18, 2025 | Elaine D Sun
Director
|
Grant | 11.0K | - |
Source: TwelveData, from SEC Form 4 filings
Questions people ask
Answered from the figures on this page, as of October 16, 2026.